NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

Go back to NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
(NASDAQ: NRXP) Delayed: 3.47 -0.02 (0.57%)
Previous Close $3.49    52 Week High
Open $3.50    52 Week Low
Day High $3.54    P/E N/A 
Day Low $3.42    EPS
Volume 705,971